Chiesi Global Rare Diseases, the rare diseases business unit of Italy’s family-run Chiesi Group, announced three poster ...

German pharma and life sciences company Merck KGaA today announced new two-year follow-up results from the Phase III MANEUVER ...

US precision oncology company IDEAYA Biosciences and partner Servier presented updated data from three trials of the oral PKC ...

China is emerging as an innovation hub in the rapidly diversifying global obesity drug landscape, with domestic drugmakers ...

Cambridge, USA based Spero Therapeutics, which is focused on developing advanced medicines for serious immune-mediated ...

Medicines that bring cancer cells into contact with immune cells are becoming part of treatment for several blood cancers and small cell lung cancer. Known as T-cell engagers, they are also being ...

Swiss pharma major Roche (ROG: SIX) has reported that its experimental lung cancer drug divarasib reduced the risk of death ...

Shares in Tango Therapeutics fell nearly 18% to $22.91 on Friday after the US biotech presented updated Phase I/II data for ...

Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation ...

US biotech major Amgen has announced landmark interim Phase III results showing that Imdelltra (tarlatamab-dlle) in combination with UK pharma major AstraZeneca's Imfinzi (durvalumab) reduced the risk ...

The US Centers for Medicare and Medicaid Services (CMS) has released the final guidelines for implementation of the GLOBE ...

UK biotech venture capital investment reached £270 million, up 44% from £187 million ($250 million) in the third quarter of ...